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ABSTRACT
Background and aims: Interleukin 26 (IL-26), a novel IL-
10-like cytokine without a murine homologue, is
expressed in T helper 1 (Th1) and Th17 cells. Currently, its
function in human disease is completely unknown. The
aim of this study was to analyse its role in intestinal
inflammation.
Methods: Expression studies were performed by reverse
transcription-PCR (RT-PCR), quantitative PCR, western blot
and immunohistochemistry. Signal transduction was ana-
lysed by western blot experiments and ELISA. Cell
proliferation was measured by MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) assay. IL-26 serum levels were determined by
an immunoluminometric assay (ILMA).
Results: All examined intestinal epithelial cell (IEC) lines
express both IL-26 receptor subunits IL-20R1 and IL-10R2.
IL-26 activates extracellular signal-related kinase (ERK)-1/
2 and stress-activated protein kinase/c-Jun N-terminal
kinase (SAPK/JNK) mitogen-activated protein (MAP)
kinases, Akt and signal transducers and activators of
transcription (STAT) 1/3. IL-26 stimulation increases the
mRNA expression of proinflammatory cytokines but
decreases cell proliferation. In inflamed colonic lesions of
patients with Crohn’s disease, an elevated IL-26 mRNA
expression was found that correlated highly with the IL-8
and IL-22 expression. Immunohistochemical analysis
demonstrated IL-26 protein expression in colonic T cells
including Th17 cells expressing the orphan nuclear
receptor RORct, with an increased number of colonic IL-
26-expressing cells in active Crohn’s disease.
Conclusion: Intestinal cells express the functional IL-26
receptor complex. IL-26 modulates IEC proliferation and
proinflammatory gene expression and its expression is
upregulated in active Crohn’s disease, indicating a role for
this cytokine system in the innate host cell response
during intestinal inflammation. For the first time, IL-26
expression is demonstrated in colonic RORct-expressing
Th17 cells in situ, supporting a role for this cell type in the
pathogenesis of Crohn’s disease.
Interleukin 26 (IL-26), initially named AK155, was
originally identified by subtraction hybridisation
coupled with representational difference analysis
as a gene upregulated in human T cells following
infection with herpesvirus saimiri (HVS), with the
capacity to transform these cells in culture.1 The
IL-26 protein has 24.7% amino acid identity and
47% amino acid similarity to human IL-10. IL-26 is
a member of the IL-10-like cytokine family
composed of cytokines with limited homology to
IL-10, including IL-10, IL-19, IL-20, IL-22, IL-24,
IL-26, IL-28A, IL-28B and IL-29. IL-28A/B and IL-29
are also known as interferon ls (IFNls). IL-26
signals through a novel receptor complex consisting
of the transmembrane proteins IL-20R1 and
IL-10R2.2 In addition to cytokine-specific ligand-
binding chains, IL-22, IL-26, IL-28A/B and IL-29 use a
common second receptor chain (IL-10R2) for assem-
bling their active receptor complexes and signalling.
The IL-26 gene is located on chromosome 12q14
in a cluster where IFNc and IL-22 are also
positioned. IL-26 forms homodimers similarly to
IL-10.1 IL-26 was originally described as a gene
upregulated upon HVS infection in T cells1 but
could also be detected in unstimulated fresh
peripheral blood cells of healthy donors by reverse
transcription-PCR (RT-PCR) analysis.1 Although
the IL-10 transcript was detected in most cell lines
of T or B cell lineage, the IL-26 transcript was
rather specific for T cells. In another study, under
basal conditions no IL-26 mRNA could be detected
in monocytes, natural killer (NK) cells or B and
T cells.3 Its expression could be induced only in NK
cells and T cells upon stimulation with IL-2/IL-12
and anti-CD3 monoclonal antibody, respectively.3
This induction of IL-26 mRNA was observed
specifically in activated memory cells (CD4+;
CD45RO+) and during polarisation toward type 1
T helper (Th1) cells.3 A recent, preliminary study
with in vitro differentiated T cells derived from
healthy human blood donors suggests that Th17
cells also express IL-26 following stimulation with
IL-23.4 Th17 cells are a newly discovered subset of
inflammatory T cells5 that differentiate in humans
under the influence of IL-1b, IL-6, IL-21 and IL-23.6
They are characterised by the expression of the
transcription factor RORct7 and the IL-23 receptor
(IL-23R).8 They produce a specific pattern of
cytokines and chemokines such as IL-17A, IL-17F,
IL-21, IL-22 and CCL20.4 9 10 Th17 cells contribute to
the pathogenesis of many inflammatory autoim-
mune diseases such as multiple sclerosis or rheuma-
toid arthritis (reviewed in Furuzawa-Carballeda et
al11) and inflammatory bowel disease (IBD).12 13
Recent findings demonstrate that a heterodimer
consisting of IL-20R1 and IL-10R2 functions as the
IL-26 receptor.2 14 This receptor complex is
expressed particularly in epithelial cells such as
keratinocytes and colonic epithelial cells.14
However, there is currently very limited informa-
tion on the biological functions of IL-26.
Interestingly, both IL-22 and IL-26 have been
identified outside of mammals, and their organisa-
tion and synteny demonstrate that this cluster of
cytokines is well conserved during evolution.15
However, in contrast to IL-22, no murine IL-26
homologue has been described so far, limiting the
experimental opportunities to study the phenotypic
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consequences of IL-26 gene knockout and IL-26-mediated func-
tions in murine models in vivo. Moreover, there are no studies on
the effects of IL-26 in human disease published so far.
Given the IL-26 receptor expression in colonic epithelial cells14
and our recent findings on the important role of other IL-10-like
cytokines such as IL-22, IL-28A and IL-29 in the regulation of
intestinal epithelial cells (IECs)16 17 and hepatic cells,18–20 we
aimed to analyse in this study signal transduction pathways and
specific biological functions mediated by IL-26 in IECs.
Recently, we demonstrated that the IL-10-related cytokine
IL-22, another Th1 and Th17 cytokine sharing the IL-10R2
subunit with IL-26 for signalling, is upregulated in intestinal
inflammation and modulates intestinal barrier function.16
Therefore, we focused in this study on the role of IL-26 in
IECs and in IBD.
MATERIALS AND METHODS
Reagents
The following antibodies were used in this study: anti-IL-26 and
anti-IL-20R1 (R&D Systems, Minneapolis, Minnesota, USA),
anti-IL-10R2 (Acris Antibodies, Herford, Germany), anti-RORct
(Abcam, Cambridge, UK), anti-pSTAT1 (BD Transduction
Laboratories, Franklin Lakes, New York, USA), anti-pSTAT3
(Upstate Biotechnology, Lake Placid, New York, USA), anti-
STAT1 and anti-STAT3 (Santa Cruz Biotechnology, Santa
Cruz, California, USA). Antibodies against phosphorylated
extracellular signal-regulated kinase (ERK)-1/2 (Thr183/
Tyr185), phosphorylated stress-activated protein kinase/c-Jun
N-terminal kinase (SAPK/JNK; Thr183/Tyr185) and phospho-
Akt (Ser473) were purchased from Cell Signaling (Beverly,
Massachusetts, USA). Anti-ERK-1/2, anti-SAPK/JNK and anti-
Akt antibodies were also from Cell Signaling. Horseradish
peroxidase (HRP)-linked antirabbit and antigoat secondary
antibodies were purchased from Amersham (Arlington
Heights, Illinois, USA) and Santa Cruz Biotechnology.
Secondary antibodies for immunohistochemistry (AlexaFluor
488 or AlexaFluor 546 coupled and peroxidase coupled) were
from Invitrogen (Karlsruhe, Germany) and Dako (Hamburg,
Germany). Fluorescein isothiocyanate (FITC)-conjugated anti-
goat antibody was from Sigma-Aldrich (Taufkirchen, Germany)
and antirabbit Cy-2 antibody was from Jackson Immuno
Research (Suffolk, UK). Recombinant human IL-26 was
obtained from R&D Systems.
Cell culture
The human colorectal cancer-derived IEC lines SW480, SW620,
Caco-2, HT-29, HCT116, T84 and DLD-1 were obtained from the
American Type Culture Collection (Rockville, Maryland, USA).
Cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) containing 100 IU/ml penicillin, 100 mg/ml streptomy-
cin and 10% heat-inactivated fetal calf serum (FCS) from PAA
(Pasching, Austria) in a humidified 5% CO2 atmosphere at 37uC.
Reverse transcription-PCR
RT-PCR was performed as previously described.21 Briefly, total
RNA was isolated using Trizol reagent (Invitrogen). A 2 mg
aliquot of DNase-treated total RNA was reverse transcribed using
the Qiagen Omniscript RT kit (Hilden, Germany). To control for
genomic contamination, an identical parallel PCR was performed
containing starting material that had not been reverse transcribed.
The primers for the PCRs are shown in table 1. The specificity of
the PCR products was verified by sequencing.
Quantitative PCR
Real-time PCR was performed with a Rotorgene RG-3000 cycler
(Corbett Research, Sydney, Australia) using the Quantitect
SYBR Green PCR Kit from Qiagen following the manufacturer’s
guidelines. Oligonucleotide primers (table 1) were designed not
to amplify genomic DNA, according to the published sequences.
The expression of each mRNA was normalised to b-actin
expression in the respective cDNA preparation.
Immunohistochemistry and immunocytochemistry
Peroxidase staining of paraffin-embedded tissue slides was
performed using standard protocols. Briefly, after deparaffinisa-
tion and demasking of antigens, endogenous peroxidases were
blocked with H2O2. Slides were blocked with 10% normal
serum and were incubated with avidin and biotin. Following
incubation with the primary antibody overnight at 4uC, slides
were incubated with the secondary, biotin-conjugated antibody.
Next, they were incubated with HRP–streptavidin, followed by
incubation with the peroxidase substrate 39-diaminobenzidine
(DAB). Slides were counterstained with haematoxylin.
Double immunofluorescent staining (anti-RORct and anti-IL-
26) of colonic tissue was performed on paraffin-embedded
tissue. Following deparaffinisation, tissue was fixed for 1 min in
a mixture of ice-cold acetic acid and methanol (1:1). Slides were
washed with Tris–Tween and were blocked for 1 h with normal
serum. The first primary antibody (anti-RORct) was incubated
overnight at 4uC and the secondary, fluorochrome-coupled
antibody was incubated for 1 h at room temperature. After
washing, incubation with the second primary antibody (anti-IL-
26) and secondary antibody was performed in the same way.
Immunofluorescence staining of HT-29 cells was performed
as described previously.22
Signal transduction experiments, protein isolation, gel
electrophoresis and immunoblotting
The signal transduction experiments were performed in over-
night serum-starved IEC lines as indicated. Cells were stimu-
lated with 100 ng/ml IL-26, unless indicated otherwise. This
concentration was based on pilot experiments demonstrating a
significantly greater effect of 100 ng/ml IL-26 for the activation of
certain kinases than lower concentrations. Cells were solubilised
in lysis buffer16 for 20 min and lysates were cleared by
centrifugation at 10 000 g for 20 min. The protein concentration
Table 1 PCR primers used for RT-PCR analysis
IL-10R2 forward 59-ggctgaatttgcagatgagca-39
IL-10R2 reverse 59-gaagaccgaggccatgagg-39
IL-20R1 forward 59-tacacccctcagctccaagact-39
IL-20R1 reverse 59-gaaggaatacacagcctgccag-39
IL-26 forward 59-ggcagaaattgagccactgt-39
IL-26 reverse 59- tccagttcactgatggctttg-39
IL-6 forward 59-aaagaggcactggcagaaaa-39
IL-6 reverse 59-gaggtgcccatgctacattt-39
IL-8 forward 59-atgacttccaagctggccgtggct-39
IL-8 reverse 59-tctcagccctcttcaaaaacttctc-39
TNFa forward 59-atgagcactgaaagcatg-39
TNFa reverse 59-tcacagggcaatgatccc-39
SOCS-3 forward 59-ttctgatccgcgacagctc-39
SOCS-3 reverse 59-tgcagagagaagctgcccc-39
b-Actin forward 59-gccaaccgcgagaagatga-39
b-Actin reverse 59-catcacgatgccagtggta-39
IL, interleukin; RT-PCR, reverse transcription-PCR; SOCS-3,
suppressor of cytokine signalling 3; TNF, tumour necrosis factor.
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of each sample was quantified by the Bradford method.
Immunoblotting was performed as previously described.23
Enzyme-linked immunosorbent assay
The BD OptEIA Human IL-8 Elisa Kit II (BD Biosciences,
Bedford, Massachusetts, USA) was used for quantification of
IL-8 release according to the manufacturer’s instructions.
IL-26 immunoluminometric assay (ILMA)
Ninety-six-well plates (Nunc Maxisorb, Nunc, Wiesbaden,
Germany) were incubated with a 1:1000 dilution of a
monoclonal anti-IL-26-antibody for 7 days at 4uC. After
blocking with 2% non-fat milk for 1 h at room temperature,
the plates were incubated with serum samples and different
dilutions of recombinant human IL-26 overnight at 4uC.
Following incubation with a biotinylated polyclonal IL-26
antibody, neutravidin–HRP was added. Femtoglow (Michigan
Diagnostics, Troy, Michigan, USA) was used as a chemolumi-
nescent substrate and luminescence was measured in a
microplate luminometer (Orion II, Berthold Detection
Systems, Pforzheim, Germany).
Cell proliferation assay
HT-29 cells were seeded onto 96-well plates at a density of 5000
cells/well and grown for 1 day. After starvation in serum-free
medium overnight, the cells were incubated with or without
IL-26 (10 and 100 ng/ml) in medium containing 0.1% FCS for
48 h. Cell proliferation was determined using the CellTiter 96
Aqueous Non-Radioactive Cell Proliferation Assay (Promega,
Madison, Wisconsin, USA) according to the manufacturer’s
instructions. Relative means (SEM) from three independent
experiments are shown.
Apoptosis assays
Apoptosis assays were performed as described previously.24 For
induction of TRAIL (tumour necrosis factor-related apoptosis-
inducing ligand)-mediated apoptosis, TRAIL at a concentration of
100 ng/ml was used, and for CD95-mediated cell death, ligand-
specific anti-APO-1 monoclonal antibody at concentrations of 500
and 1000 ng/ml was used. Cells were incubated for 24 h with the
respective ligands and with or without IL-26 (10 or 100 ng/ml).
Cells were harvested and were lysed in hypotonic lysis buffer
(0.1% sodium citrate and 0.1% Triton X-100) containing 50 mg/ml
propidium iodide, and were incubated at 4uC overnight. The
nuclei were then analysed for DNA content by flow cytometry.
Colonic biopsies
All participating patients with IBD were recruited by the IBD
center of the University-Hospital Munich-Grosshadern
(Germany) and gave written, informed consent prior to biopsy
Figure 1 Interleukin 20 receptor 1
(IL-20R1) and IL-10R2 are expressed in
intestinal epithelial cells (IECs). (A) mRNA
expression of IL-20R1 and IL-10R2 as
analysed by reverse transcription-PCR
analysis of mRNA derived from IEC lines
as indicated. IL-26 expression was not
detected in any cell line (data not shown).
(B, C) IL-20R1 and IL-10R2 proteins are
expressed in IECs as demonstrated by
western blot analysis in HT-29 and
SW480 cells (left panels, 85 mg protein/
lane) and by indirect immunofluorescence
experiments (middle panels) in HT-29
cells using a fluorescein isothiocyanate
(FITC)-labelled secondary antibody.
Nuclei (blue) were stained with Hoechst
33342. In the negative control (right
panels), the first antibody was omitted.
GAPDH, glyceraldehyde phosphate
dehydrogenase.
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sampling. The study was approved by the Ethics Committee of
the Medical Faculty of the University of Munich. Biopsies were
taken from patients with Crohn’s disease and ulcerative colitis
undergoing diagnostic colonoscopy. Patients with indetermi-
nate colitis were excluded from the study. Demographic and
clinical data were recorded by analysis of patient charts and a
detailed questionnaire including an interview at the time of
enrolment. The demographic data are summarised in table 2.
The diagnosis of Crohn’s disease or ulcerative colitis was
determined according to established guidelines based on
endoscopic, histopathological and radiological criteria.
From each patient, four biopsies were collected: two from
macroscopically non-inflamed sites and two from macroscopically
inflamed mucosa. IL-26 and IL-8 mRNA levels were measured in
each individual biopsy. For quantification, the average IL-26 and
IL-8 mRNA expression of the two non-inflamed biopsies was
compared with the average expression in the two inflamed
biopsies (all normalised to b-actin expression). In addition, IL-22
mRNA levels of these biopsies were available from a previous
study16 and were included in the correlation analysis.
Statistical analysis
Statistical analysis was performed using two-tailed Student t
test. A p values ,0.05 was considered as significant. Measured
values that differed from the means by more than four times the
standard deviation were considered as outliers and were not
included in the statistical analysis.
RESULTS
IECs express the IL-26 receptor complex
To utilise a cell system to study this ligand–receptor system,
we first analysed if the IL-26 receptor complex consisting of
IL-10R2 and IL-20R1 is expressed in IEC lines. RT-PCR for
IL-10R2 and IL-20R1 mRNA was performed in several IEC cell
lines (HT-29, SW480, SW620, HCT116, Caco-2, T84 and DLD-
1). RT-PCR analysis demonstrated IL-10R2 and IL-20R1 mRNA
expression in all IEC lines tested (fig 1A), while IL-26 was not
expressed (data not shown). The hepatic cell line HepG2 does
not express IL-20R1 (data not shown) and served as a negative
control cell line in the following signal transduction experi-
ments. The expression of both IL-26 receptor subunits on the
protein level was confirmed by western blot analysis of total
protein extracts of HT-29 and SW480 cells (fig 1B,C; left panels)
and by indirect immunofluorescence staining (fig 1B,C; middle
panels) using specific antibodies against IL-20R1 and IL-10R2.
IL-26 induces STAT1/3, ERK-1/2, SAPK/JNK-1/2 and Akt
phosphorylation
Next, we studied if the IL-26 receptor complex expressed by
IECs is functional by analysing major intracellular signalling
pathways. Since previous studies reported activation of STAT
signalling by IL-26,2 14 we performed western blot analysis and
Figure 2 Interleukin 26 (IL-26) induces activation of the transcription
factors signal transducers and activators of transcription 1 (STAT1) and
STAT3. Following stimulation of HT-29 cells with IL-26 (100 ng/ml),
increased phosphorylation was observed for STAT1 (A) and STAT3 (B).
One representative experiment (n = 3) is shown. (C) Densitometric
analysis of STAT1 and STAT3 phosphorylation.
Figure 3 Interleukin 26 (IL-26) stimulation leads to extracellar signal-
regulated kinase (ERK)-1/2, stress-activated protein kinase/c-Jun N-
terminal kinase (SAPK/JNK)-1/2 and Akt phosphorylation. IL-26 induces
rapid activation of the mitogen-activated protein kinases ERK (A) and
SAPK/JNK (B) and of Akt (C), reaching maximal phosphorylation levels
after 15 min. One representative experiment (n = 3) is shown. (D)
Densitometric analysis of ERK, SAPK/JNK and Akt phosphorylation.
Intestinal inflammation
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investigated the influence of IL-26 on the phosphorylation levels
of STAT1 and STAT3 in IECs. In comparison with basal STAT1
phosphorylation in unstimulated cells, a strong STAT1 tyrosine
phosphorylation was observed upon IL-26 stimulation starting
5 min after cytokine stimulation (fig 2A). IL-26 also induced
tyrosine phosphorylation of STAT3 which was strongest after
10 min of stimulation (fig 2B). Densitometric analysis of the
phosphorylation blots demonstrated a 14.5- and 22.8-fold
increase in phosphorylation for STAT1 and STAT3, respectively
(fig 2C). In contrast, in HepG2 cells, which lack the IL-20R1
subunit, no STAT activation was detected after IL-26 stimula-
tion, demonstrating that the IL-20R1 subunit is essential for
IL-26 signalling (data not shown). In addition, ERK-1/2
mitogen-acivated protein (MAP) kinases (fig 3A) and—to a
lesser degree—SAPK/JNK kinases (fig 3B) were transiently
activated by 100 ng/ml IL-26. Moreover, IL-26 induced phos-
phorylation of Akt (fig 3C). The maximum ERK, SAPK/JNK and
Akt activation was 15 min after cytokine stimulation (fig 3D),
whereas the maximal STAT1/3 phosphorylation levels were
already reached 10 min after IL-26 stimulation (fig 2C).
IL-26 decreases proliferation but does not influence apoptosis in
IECs
Recently, we demonstrated that activation of ERK MAP
kinases, Akt and STAT proteins following stimulation with
chemokines or IL-22 mediates IEC proliferation,16 25 26 while
STAT activation following IL-28A and IL-29 stimulation
mediates antiproliferative signals in IECs.17 Therefore, we
analysed the effect of IL-26 on IEC proliferation in the following
experiments. Similar to IL-28A and IL-29,17 IL-26 had a modest
antiproliferative effect on IECs. Compared with cytokine-free
medium-stimulated controls, IEC proliferation was diminished
by 22% following stimulation with 10 and 100 ng/ml IL-26
(fig 4A, p = 0.05). However, IL-26 did not significantly influence
apoptosis induced by TRAIL or by anti-APO-1 treatment in
HT-29 cells (data not shown).
IL-26 increases expression of proinflammatory cytokines
After demonstrating that the IL-26 receptor complex is
functional in IECs, we next examined transcriptional targets
of this cytokine. Previously, we identified SOCS-3 as a STAT1/
3-dependent gene.27 Therefore, we analysed SOCS-3 mRNA
levels in IECs stimulated with IL-26. As shown in fig 4B, IL-26
treatment induced SOCS-3 mRNA expression significantly
(p,0.005), reaching a maximum increase of 13.8-fold after
24 h. Next, we analysed the role of IL-26 on the transcriptional
regulation of the proinflammatory cytokines tumour necrosis
factor a (TNFa), IL-8 and IL-6, three major inflammatory
mediators in IECs, as downstream readout of IL-26-mediated
gene expression. While IL-6 mRNA expression did not change
significantly after IL-26 stimulation (data not shown), IL-26
enhanced TNFa and IL-8 mRNA expression 35.1- and 18.0-fold,
respectively (p,0.05), as measured by quantitative PCR (fig 4B).
Similarly, we measured a 3.7-fold increased IL-8 protein release
by ELISA following IL-26 stimulation (fig 4C).
IL-26 mRNA expression is increased in the inflamed colonic
mucosa of patients with Crohn’s disease
Since we established that IL-26 upregulates the expression of
proinflammatory cytokines in IECs, we next analysed by real-time
PCR its expression in intestinal inflammation in vivo. This analysis
included a total of 88 biopsy samples taken from 22 different
patients with IBD (Crohn’s disease: n = 12; ulcerative colitis:
n = 10). The demographics of these patients and the anatomic
segment of the biopsy sampling are summarised in table 2.
Ileal and colonic biopsies were taken from sites with
endoscopically (macroscopic) inflamed colonic mucosa and
were compared with those of endoscopically non-inflamed
colonic mucosa taken from the same 22 patients. In patients
with Crohn’s disease, the colonic IL-8 mRNA expression, which
was determined as a standard inflammatory marker, was
5.9-fold higher in the inflamed biopsy samples compared with
uninflamed biopsies (p,0.05; table 2).
Similarly, we measured increased IL-26 mRNA expression in
inflamed colonic biopsies compared with non-inflamed colonic
tissue (increase between 1.1- and 15.0-fold; table 2). The
increases in IL-8 and IL-26 expression in inflamed biopsies were
Figure 4 Interleukin 26 (IL-26) decreases cell proliferation and enhances
mRNA expression of proinflammatory cytokines and suppressor of cytokine
signalling 3 (SOCS-3). (A) Compared with medium-stimulated controls, 10
and 100 ng/ml IL-26 decreased proliferation of HT-29 cells (*p = 0.05). The
experiment was performed in triplicate. (B) Significant upregulation of IL-8,
tumour necrosis factor a (TNFa) and SOCS-3 mRNA expression after
stimulation of HT-29 cells with 100 ng/ml IL-26 as determined by
quantitative PCR. mRNA expression at the start of the experiment (0 h)
was arbitrarily set to 1.0. Data are derived from two independent
experiments. *p,0.05, **p,0.005, ***p,0.0005. (C) IL-8 protein levels
increase up to 3.7-fold and reach a maximum after 12 h of IL-26
stimulation. The IL-8 protein concentration was determined by ELISA.
Intestinal inflammation
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highly related to each other (correlation coefficient r = 0.96;
fig 5A). Although there was also a high correlation between IL-8
and IL-26 mRNA expression in patients with ulcerative colitis
(r = 0.79; fig 5B) and IL-8 expression was significantly increased
up to 8.1-fold in the inflamed tissue (p = 0.02; table 2), the
difference in IL-26 mRNA expression in inflamed and non-
inflamed biopsies did not reach statistical significance (p = 0.08)
in patients with ulcerative colitis.
Next, we compared IL-26 expression with the expression of
IL-22, another IL-10-like cytokine expressed in Th17 cells. IL-22
expression data were available from a previous study.16
Interestingly, the increase in IL-26 expression in inflamed
colonic tissue correlated highly with the increase in IL-22
expression (fig 5C,D) in patients with Crohn’s disease and
ulcerative colitis (r = 0.81 for Crohn’s disease; r = 0.89 for
ulcerative colitis).
IL-26 serum protein expression is higher in patients with Crohn’s
disease compared with controls
In addition, we developed an ILMA as described in the Materials
and methods section for the detection of IL-26 protein using a
monoclonal IL-26 antibody for capturing and a polyclonal IL-26
antibody for detection. To determine if the increased colonic
IL-26 mRNA expression in patients with Crohn’s disease is
mirrored by an increased IL-26 serum expression, we analysed the
IL-26 protein expression in the sera of 40 patients with Crohn’s
disease and 39 unrelated controls by ILMA. Analysis revealed
significantly higher IL-26 serum levels in patients with Crohn’s
disease (mean concentration 2.42 ng/ml, range 0.79–17.56) in
comparison with control patients (mean concentration 1.17 ng/ml,
range 0.56–4.17; p,0.01 vs Crohn’s disease).
Intestinal RORct-expressing Th17 cells produce IL-26 and their
number is increased in active Crohn’s disease
To analyse further expression of IL-26 in colonic tissue in situ
and to clarify which cells produce IL-26, we performed a detailed
immunohistochemical analysis for IL-26 in inflamed and non-
inflamed colonic tissue of patients with Crohn’s disease. As
shown in the representative images of this analysis in fig 6A and
B, IL-26 is expressed in infiltrating immune cells but not in
epithelial cells. Importantly, the number of IL-26-expressing
cells in inflamed colonic tissue of patients with Crohn’s disease
(fig 6D,E) was higher than in uninflamed tissue (fig 6A,B) which
is consistent with our quantitative PCR analysis of colonic IL-26
mRNA expression (table 2).
A preliminary study of Th17 cells from healthy donors
differentiated from peripheral T cells in vitro suggested Th17
cells as the source of IL-26 production.4 To clarify if colonic
Th17 cells express IL-26 in situ, we performed co-staining using
specific antibodies directed against IL-26 and RORct, a
transcription factor that is specifically expressed in Th17 cells.7
Examples of this immunohistochemical analysis shown in fig 7
Table 2 Demographic data of patients and results of the cytokine expression analysis using quantitative PCR
Patient
number Sex
Age at
diagnosis
(years)
Disease
duration
(years) Current medication
Anatomic site of biopsy sampling IL-26
expression
inflamed vs
non-inflamed
IL-8 expression
inflamed vs
non-inflamed
IL-22
expression
inflamed vs
non-inflamedNon-inflamed Inflamed
CD1 F 21 16 AZA, IFX Caecum* Terminal ileum* 1.32 4.50 1.59
CD2 M 18 16 Mesalazine, AZA Descending colon Descending colon 8.30 11.67 3.67
CD3 F 25 15 None Colon Colon 2.31 1.50 0.32
CD4 F 28 1 AZA Caecum* Terminal ileum* 6.22 11.08 1.92
CD5 F 29 1 Mesalazine,
corticosteroids
Caecum* Terminal ileum* 1.12 1.52 1.50
CD6 F 29 22 None Descending colon Descending colon 0.52 1.41 2.81
CD7 F 18 5 MTX Caecum* Terminal ileum/
ileocaecal valve*
15.03 31.12 13.58
CD8 M 36 17 AZA Transverse colon Transverse colon 0.85 2.24 3.07
CD9 M 50 1 None Ascending colon* Terminal ileum* 1.86 0.97 ND
CD10 M 36 17 Corticosteroids Caecum* Terminal ileum* 3.72 1.45 1.37
CD11 M 25 6 AZA Colon Colon 0.53 1.35 ND
CD12 M 26 7 AZA Caecum Caecum 0.29 4.26 3.35
Average
(SEM)
28.4 (2.6) 10.3 (2.2) Crohn’s disease 3.52 (1.27) 5.85 (2.55) 3.32 (1.18)
UC1 F 65 5 Corticosteroids Sigmoid* Rectum* 1.77 6.97 0.52
UC2 M 48 1 Mesalazine, budenosid Descending colon Descending colon 1.78 2.37 0.97
UC3 M 74 2 AZA rectum Rectum 0.78 0.94 0.72
UC4 F 39 5 None Transverse colon Transverse colon 2.75 2.01 3.25
UC5 M 39 3 None Caecum* Rectum* 8.66 8.12 5.74
UC6 M 57 6 AZA, corticosteroids,
mesalazine
Caecum Caecum 0.36 2.64 ND
UC7 M 36 6 6-MP Sigmoid Sigmoid 1.63 5.82 1.82
UC8 F 34 4 None Sigmoid Sigmoid 5.73 3.27 2.42
UC9 B 34 8 6-MP, mesalazine,
corticosteroids
Caecum* Ascending colon* 1.72 0.49 1.76
UC10 M 34 9 MTX Sigmoid* Rectum* 0.89 2.44 0.84
Average
(SEM)
46.0 (4.6) 4.9 (0.8) Ulcerative colitis 2.61 (0.78) 3.31 (0.83) 2.00 (0.55)
The current medical therapy and the anatomic site, from which the samples were taken, are given for all patients. Biopsy sampling for inflamed and non-inflamed lesions was aimed
to be taken in the same colonic or ileal segment. This was not possible in patients marked with an asterisk due to severe inflammation in the whole anatomic segment. Therefore,
biopsies from a bordering (non-inflamed) segment were included for comparison.
AZA, azathioprine; F, female; IFX, infliximab; M, male; 6-MP, 6-mercaptopurine; MTX, methotrexate; ND, not determined
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Figure 5 Intestinal interleukin 26 (IL-26)
mRNA expression is upregulated in
inflammatory bowel disease and
correlates with IL-8 and IL-22 mRNA
expression. (A, B) The increase of IL-26
mRNA expression in inflamed colonic and
ileal biopsies (in comparison with
uninflamed tissue) correlated highly with
the respective IL-8 mRNA expression in
Crohn’s disease (CD) (A, r = 0.96) and
ulcerative colitis (UC) (B, r = 0.79). (C, D)
High correlation between the increase of
mRNA expression of IL-26 and IL-22,
another IL-10-related T helper 17 (Th17)
cytokine, in inflamed intestinal biopsies
from patients with (C) CD and (D) UC
(r = 0.81 and 0.89, respectively).
Figure 6 The number of infiltrating interleukin 26 (IL-26)-positive immune cells is increased in active Crohn’s disease. Representative
immunoperoxidase analysis of IL-26 expression of uninflamed colonic tissue (A–C) and inflamed colonic tissue (D–F) taken from a patient with Crohn’s
disease. In the negative controls, the secondary antibody was omitted. Original magnification was 620 (A, C, D, F), (B, E) Detail from A and D,
respectively.
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demonstrate that a considerable number of RORct-expressing
Th17 cells also express IL-26, while, however, not all Th17 cells
are producers of IL-26. One difficulty of this analysis is the fact
that RORct and IL-26 are expressed in two different cell
compartments (RORct in the nucleus and IL-26 in the cytosol).
Therefore, RORct-expressing Th17 cells, which are imaged only
on a cytosolic cross-section, will not appear RORct-positive on
such a cross-sectional image. To demonstrate the expression of
RORct and IL-26 in different cell compartments, we performed
reconstructional analysis of cross-sectional images of single cells.
A video sequence of such sequential cross-sections of a single cell
imaged by confocal microscopy can be found in the
Supplemental materials online (Video file S1). Frames of this
video sequence are shown in fig. 8A–F, demonstrating the
nuclear expression of RORct and the cytosolic expression of
IL-26. Interestingly, cross-sections taken outside of the nucleus
(fig 8E,F) appear not to be stained for RORct. Only in Th17 cells
with very strong IL-26 and RORct expression did IL-26 and
RORct staining appeared to ‘‘co-localise’’ in the perinuclear
region (fig 8F–I).
DISCUSSION
This study represents the first report demonstrating a role for
IL-26 in human disease. IL-26 is a novel member of the IL-10-like
cytokine family and shares with IL-10 the IL-10R2 subunit for
signalling. While IL-10 has anti-inflammatory properties, we
here demonstrate that IL-26 has proinflammatory functions in
IECs and is upregulated in IBD. Recently, our group also
demonstrated proinflammatory functions for IL-22, another
IL-10-like cytokine in IECs.16 Similar to IL-22,16 IL-26 upregulates
the gene expression of proinflammatory cytokines in IECs. In
addition, we demonstrate functional IL-26 receptor expression
in IECs. IL-26 activates ERK and SAPK/JNK MAP kinases, Akt
and STAT proteins in IECs, which are the major signalling
pathways of other proinflammatory cytokines with increased
expression in IBD such as IL-2216 and IL-31.22 In contrast, cell
lines such as HepG2, which do not express the IL-20R1 subunit,
are not responsive to IL-26 treatment.
It has been shown that activated T cells are a major source of
IL-26 production.1 3 Depending on the T cell source of cytokine
production, cytokines have been differentiated in Th1 and Th2
cytokines. Previous studies demonstrated an induction of IL-26
production particularly in Th1 cells.3 Crohn’s disease is
considered to represent a Th1- and Th17-mediated intestinal
inflammation, while ulcerative colitis has, at least to some
degree, features of Th2-mediated colitis.28 29 Consistent with
this observation, in our study the relative upregulation of IL-26
expression (compared with uninflamed tissue) was more
pronounced in inflamed lesions of patients with Crohn’s disease
compared with patients with ulcerative colitis. Moreover,
colonic IL-26 mRNA expression correlated strongly with IL-8
and IL-22 mRNA expression, confirming IL-26 as a marker of
intestinal inflammation.
Our detailed immunohistochemical analysis revealed for the
first time IL-26 protein expression in situ. There was an
increased number of IL-26-expressing cells in active Crohn’s
disease which correlated with the results of our quantitative
PCR analysis of colonic biopsy tissue taken from inflamed and
uninflamed mucosa affected by Crohn’s disease. IL-26 expres-
sion was found in infiltrating intestinal T cells including
RORct-expressing Th17 cells, but not in primary IECs. This is
of particular interest, since very recent evidence suggests that
Th17 cells contribute to the pathogenesis of IBD, particularly
Crohn’s disease.28 This is also supported by a recent genome-
wide association study demonstrating IL23R, which is expressed
by Th17 cells, to be a Crohn’s disease susceptibility gene.30 We
recently confirmed IL23R as an IBD susceptibility gene in the
German population.31 Interestingly, we demonstrated that the
genetic risk for Crohn’s disease mediated by IL23R is directly
linked to the expression of the proinflammatory cytokine IL-2232
which is also expressed in Th17 cells.4 Moreover, we and others
Figure 7 Interleukin 26 (IL-26) is expressed in colonic RORct-
expressing T helper 17 (Th17) cells in active Crohn’s disease.
Immunofluorescence analysis of colonic IL-26 (A, E) and RORct
expression (B, F) in colonic tissue in situ from patients with Crohn’s
disease. (C) (merged image of A and B) and (G) (merged image of E and
F) demonstrate that a number of RORct+ Th17 cells also express IL-26.
D and H are images from C and D overlaid with the phase contrast
microscopic image from the same section, demonstrating the lack of
IL-26 expression in colonic intestinal epithelial cells.
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demonstrated an increased expression of Th17 cytokines and
chemokines such as IL-17A, IL-17F, IL-22 and CCL20 in active
Crohn’s disease.16 32–35
Here, we show significantly increased IL-26 serum levels in
patients with Crohn’s disease compared with healthy controls.
However, overall IL-26 serum levels were rather low, which is
probably related to the fact that only less than 1% of cells in the
peripheral blood are Th17 cells.36 In contrast, the high number
of infiltrating RORct-expressing intestinal Th17 cells in active
Crohn’s disease suggests an important role for this cell type in
local tissue inflammation. IL-26-producing Th17 cells are likely
to sustain intestinal inflammation since we demonstrate here
that IL-26 upregulates the gene transcription of several
proinflammatory cytokines such as IL-8 and TNFa in IECs,
while its own expression is upregulated in IBD. A recent study
demonstrated that peripheral T cells, which differentiated under
the influence of IL-23 and IL-1b to Th17 cells, produce IL-26,
supporting Th17 cells as a major source of IL-26 production.4 In
contrast, IL-23 is mainly produced in ileal dendritic cells.37 We
and others recently demonstrated that ileal dendritic cells play a
Figure 8 Interleukin 26 (IL-26) and RORct expression are confined to different cellular compartments. (A–F) Sequential single cell images derived from
cross-sectional confocal microscopic imaging using an anti-IL-26 antibody (secondary antibody AlexaFluor 488 labelled) and anti-RORct antibody
(secondary antibody AlexaFluor 546 coupled) demonstrating nuclear expression of RORct (red) and cytosolic expression of IL-26 (green). The
corresponding video file can be found in the Supplementary data (Video file S1) online. (G–I) Only in cells with very high IL-26 (G) and RORct expression
(H) was an impression of ‘‘co-localisation’’ in the perinuclear region visualised in the merged images (I).
Intestinal inflammation
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major role in the luminal sampling of bacterial pathogens,38
thereby potentially linking defects in the antibacterial defence
with the pathogenesis of Crohn’s disease.
In addition, we demonstrate that IL-26 is functional in IECs.
IL-26-induced STAT1/3 activation results in increased SOCS-3
mRNA expression. This confirms our previous studies demon-
strating that SOCS-3 is an immediate early transcriptional
target of STAT1/3.16 27 Interestingly, in Crohn’s disease,
increased colonic STAT1 phosphorylation and SOCS-3 protein
levels were found,39 supporting our findings of a proinflamma-
tory role for IL-26 in Crohn’s disease. Another study demon-
strated in a murine colitis model that SOCS-3 plays a negative
regulatory role in STAT3 activation and intestinal inflamma-
tion.40 In addition, we recently showed that signalling of other
IL-10-like cytokines such as IL-22 and the IFNls IL-28A and IL-29
is abrogated by increased expression of SOCS proteins in hepatic
cell lines18 19 41 and neuroendocrine cells.26 This suggests that IL-10-
like cytokines increase the expression of SOCS-3 and proinflam-
matory cytokines, while in turn SOCS-3 has a negative feedback
on the expression and signalling of these cytokines. Interestingly,
we found a similar mechanism for the signalling mediated by
IFNa42 and IFNb.43 Moreover, similar to the results of our studies
with IL-28A and IL-29,17 26 44 45 two other IL-10-related cytokines,
IL-26 mediates antiproliferative effects in IECs.
In summary, this is the first report on the role of IL-26 in
human disease, particularly IBD. Here, we demonstrate that IECs
express the functional IL-26 receptor complex. IL-26 activates
STAT1/3, Akt, ERK and SAPK/JNK MAP kinases and upregulates
the expression of proinflammatory cytokines and of SOCS-3
mRNA. In addition, IL-26 mRNA expression is upregulated in
inflamed colonic lesions of patients with Crohn’s disease due to an
increased infiltration of IL-26-expressing immune cells including
RORct-expressing Th17 cells. Colonic IL-26 expression in IBD
correlates highly with the expression of IL-22, another Th17
cytokine. However, the functional analysis of IL-26, particularly
in murine models of intestinal inflammation, is limited by the fact
that the IL-26 gene is not expressed in mice. In conclusion, our
data indicate a role for this novel cytokine system in promoting
proinflammatory gene transcription, suggesting a role in intest-
inal inflammation. Considering the recent progress in IBD
genetics and the identification of IL23R as an IBD susceptibility
gene30 31 and of IL26 as a susceptibility gene for ulcerative colitis,46
IL-26 is probably an important effector cytokine by which Th17
cells contribute to the pathogenesis of IBD.
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Robin Spiller, Editor
Atypical dyspepsia
CLINICAL PRESENTATION
A 68-year-old man with a history of dyspepsia and hiatus hernia
presented with 15 kg weight loss with occasional nausea and
vomiting episodes over the previous year. He was not taking
any regular medication. He underwent gastroscopy, colono-
scopy and barium swallow 1 year earlier to investigate change
in bowel habit and dyspepsia. These tests revealed hiatus hernia
and a non-specific motility disorder of the distal oesophageal
segment. Clinical examination was unremarkable.
Blood tests were all normal. An ultrasound scan of the
abdomen was normal and repeat gastroscopy again showed
only hiatus hernia. A chest x ray, which was performed in view
of weight loss and smoking history, was normal.
Symptoms initially improved with regular domperidone;
however, vomiting became more frequent and occurred in
association with abdominal pain.
A repeat ultrasound scan of the abdomen was arranged (fig 1).
QUESTION
What is the diagnosis?
See page 1288 for the answer.
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Figure 1 Ultrasound of the abdomen. The small bowel can be seen
with its accompanying echogenic mesenteric fat (black arrow). There is
an abnormal surrounding darker ring (white arrow).
Editor’s quiz: GI snapshot
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